{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:20Z","timestamp":1789013300420,"version":"build-2803163510"},"reference-count":66,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Children with Down syndrome (DS) have a greater than 100-fold increased risk of developing acute myeloid leukemia (ML) and an approximately 30-fold increased risk of acute lymphoblastic leukemia (ALL) before their fifth birthday. ML-DS originates in utero and typically presents with a self-limiting, neonatal leukemic syndrome known as transient abnormal myelopoiesis (TAM) that is caused by cooperation between trisomy 21\u2013associated abnormalities of fetal hematopoiesis and somatic N-terminal mutations in the transcription factor GATA1. Around 10% of neonates with DS have clinical signs of TAM, although the frequency of hematologically silent GATA1 mutations in DS neonates is much higher (~25%). While most cases of TAM\/silent TAM resolve without treatment within 3 to 4 months, in 10% to 20% of cases transformation to full-blown leukemia occurs within the first 4 years of life when cells harboring GATA1 mutations persist and acquire secondary mutations, most often in cohesin genes. By contrast, DS-ALL, which is almost always B-lineage, presents after the first few months of life and is characterized by a high frequency of rearrangement of the CRLF2 gene (60%), often co-occurring with activating mutations in JAK2 or RAS genes. While treatment of ML-DS achieves long-term survival in approximately 90% of children, the outcome of DS-ALL is inferior to ALL in children without DS. Ongoing studies in primary cells and model systems indicate that the role of trisomy 21 in DS leukemogenesis is complex and cell context dependent but show promise in improving management and the treatment of relapse, in which the outcome of both ML-DS and DS-ALL remains poor.<\/jats:p>","DOI":"10.1182\/hematology.2022000395","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:07:54Z","timestamp":1670602074000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Leukemogenesis in infants and young children with trisomy 21"],"prefix":"10.1182","volume":"2022","author":[{"given":"Irene","family":"Roberts","sequence":"first","affiliation":[{"name":"Department of Paediatrics and MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"9199","key":"2022120916074747600_hem2022000395C1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down's syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"key":"2022120916074747600_hem2022000395C2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2021.03.001","article-title":"Leukemia risk in a cohort of 3.9 million children with and without Down syndrome","volume":"234","author":"Marlow","year":"2021","journal-title":"J Pediatr"},{"issue":"1","key":"2022120916074747600_hem2022000395C3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","article-title":"Down syndrome","volume":"6","author":"Antonarakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2022120916074747600_hem2022000395C4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1046\/j.1365-2141.2003.04229.x","article-title":"Transient leukaemia\u2014a benign form of leukaemia in newborn infants with trisomy 21","volume":"120","author":"Zipursky","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"2022120916074747600_hem2022000395C5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","article-title":"Low risk of solid tumors in persons with Down syndrome","volume":"18","author":"Hasle","year":"2016","journal-title":"Genet Med"},{"issue":"24","key":"2022120916074747600_hem2022000395C6","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2022120916074747600_hem2022000395C7","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2022120916074747600_hem2022000395C8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cancers14061583","article-title":"Immunophenotypic analysis of acute megakaryoblastic leukemia: a EuroFlow study","volume":"14","author":"Brouwer","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2022120916074747600_hem2022000395C9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2022120916074747600_hem2022000395C10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of The World Health Organization Classification of Hematolymphoid Tumors: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2022120916074747600_hem2022000395C11","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2022120916074747600_hem2022000395C12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"3","key":"2022120916074747600_hem2022000395C13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1172\/JCI75714","article-title":"Pluripotent stem cells reveal erythroid-specific activities of the GATA1\u200aN-terminus","volume":"125","author":"Byrska-Bishop","year":"2015","journal-title":"J Clin Invest"},{"issue":"19","key":"2022120916074747600_hem2022000395C14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019001234","article-title":"Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1\u200aN terminus in erythropoiesis","volume":"134","author":"Ling","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2022120916074747600_hem2022000395C15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng1566","article-title":"Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1","volume":"37","author":"Li","year":"2005","journal-title":"Nat Genet"},{"issue":"6","key":"2022120916074747600_hem2022000395C16","doi-asserted-by":"crossref","first-page":"e1000123","DOI":"10.1371\/journal.pbio.1000123","article-title":"Direct binding of pRb\/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis","volume":"7","author":"Kadri","year":"2009","journal-title":"PLoS Biol"},{"issue":"6","key":"2022120916074747600_hem2022000395C17","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2022120916074747600_hem2022000395C18","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2022120916074747600_hem2022000395C19","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/s41375-020-0769-1","article-title":"Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation","volume":"34","author":"Lukes","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2022120916074747600_hem2022000395C20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/ng1825","article-title":"An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis","volume":"38","author":"Hollanda","year":"2006","journal-title":"Nat Genet"},{"issue":"21","key":"2022120916074747600_hem2022000395C21","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1182\/blood.2021011463","article-title":"Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype","volume":"139","author":"Hasle","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2022120916074747600_hem2022000395C22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/pbc.24944","article-title":"Loss of GATA-1 full length as a cause of Diamond-Blackfan anemia phenotype","volume":"61","author":"Parrella","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2022120916074747600_hem2022000395C23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2002-11-3599","article-title":"Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21","volume":"102","author":"Rainis","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2022120916074747600_hem2022000395C24","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood-2003-10-3383","article-title":"Natural history of GATA1 mutations in Down syndrome","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2022120916074747600_hem2022000395C25","doi-asserted-by":"crossref","first-page":"F67","DOI":"10.1136\/archdischild-2014-308004","article-title":"Prenatal therapy in transient abnormal myelopoiesis: a systematic review","volume":"101","author":"Tamblyn","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"43","key":"2022120916074747600_hem2022000395C26","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1073\/pnas.1211405109","article-title":"Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21","volume":"109","author":"Roy","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2022120916074747600_hem2022000395C27","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"2022120916074747600_hem2022000395C28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2019.08.014","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"2022120916074747600_hem2022000395C29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.15390","article-title":"Guidelines for the investigation and management of transient leukaemia of Down syndrome","volume":"182","author":"Tunstall","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2022120916074747600_hem2022000395C30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41431-020-00748-y","article-title":"Estimation of the number of people with Down syndrome in Europe","volume":"29","author":"de Graaf","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"2022120916074747600_hem2022000395C31","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-021-01128-1","article-title":"Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia","volume":"35","author":"Goemans","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2022120916074747600_hem2022000395C32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5858\/2002-126-0474-TMDWED","article-title":"Transient myeloproliferative disorder with erythroid differentiation in Down syndrome","volume":"126","author":"Bozner","year":"2002","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"2022120916074747600_hem2022000395C33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/leu.2013.373","article-title":"GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia","volume":"28","author":"Maroz","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2022120916074747600_hem2022000395C34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ajh.24420","article-title":"Basophilic differentiation in transient abnormal myelopoiesis","volume":"91","author":"Bain","year":"2016","journal-title":"Am J Hematol"},{"issue":"15","key":"2022120916074747600_hem2022000395C35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2016-09-687871","article-title":"The GATA factor revolution in hematology","volume":"129","author":"Katsumura","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2022120916074747600_hem2022000395C36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/a-1532-2016","article-title":"Recommendations for diagnosis and treatment of children with transient abnormal myelopoiesis (TAM) and myeloid leukemia in Down syndrome (ML-DS)","volume":"233","author":"Al-Kershi","year":"2021","journal-title":"Klin Padiatr"},{"issue":"13","key":"2022120916074747600_hem2022000395C37","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/bloodadvances.2018018945","article-title":"Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study","volume":"2","author":"Flasinski","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2022120916074747600_hem2022000395C38","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41375-021-01171-y","article-title":"Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome","volume":"35","author":"Yamato","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2022120916074747600_hem2022000395C39","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is essential for the treatment of ML-DS independent of post-induction MRD: results of the COG AAML1531 trial","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2022120916074747600_hem2022000395C40","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1016\/S2352-3026(21)00272-6","article-title":"Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study","volume":"8","author":"Michels","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"2022120916074747600_hem2022000395C41","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2022120916074747600_hem2022000395C42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"13","key":"2022120916074747600_hem2022000395C43","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2022120916074747600_hem2022000395C44","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2022120916074747600_hem2022000395C45","doi-asserted-by":"crossref","first-page":"E4030","DOI":"10.1073\/pnas.1702489114","article-title":"Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome","volume":"114","author":"Schwartzman","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"August","key":"2022120916074747600_hem2022000395C46","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1038\/ncomms5654","article-title":"Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations","volume":"5","author":"Nikolaev","year":"2014","journal-title":"Nat Commun"},{"issue":"15","key":"2022120916074747600_hem2022000395C47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.2018890764","article-title":"Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"50","key":"2022120916074747600_hem2022000395C48","doi-asserted-by":"crossref","first-page":"21719","DOI":"10.1073\/pnas.1006981107","article-title":"Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia","volume":"107","author":"Paulsson","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2022120916074747600_hem2022000395C49","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1111\/cas.14160","article-title":"Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome","volume":"110","author":"Kubota","year":"2019","journal-title":"Cancer Sci"},{"issue":"4","key":"2022120916074747600_hem2022000395C50","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/HS9.0000000000000053","article-title":"Advances in B-cell precursor acute lymphoblastic leukemia genomics","volume":"2","author":"Schwab","year":"2018","journal-title":"Hemasphere"},{"issue":"18","key":"2022120916074747600_hem2022000395C51","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.3390\/cancers13184597","article-title":"Copy number changes and allele distribution patterns of chromosome 21 in B cell precursor acute lymphoblastic leukemia","volume":"13","author":"Abbasi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7880","key":"2022120916074747600_hem2022000395C52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41586-021-03929-x","article-title":"Blood and immune development in human fetal bone marrow and Down syndrome","volume":"598","author":"Jardine","year":"2021","journal-title":"Nature"},{"issue":"1","key":"2022120916074747600_hem2022000395C53","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1038\/s41598-018-26123-y","article-title":"Downregulation of endothelin receptor B contributes to defective B cell lymphopoiesis in trisomy 21 pluripotent stem cells","volume":"8","author":"MacLean","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"2022120916074747600_hem2022000395C54","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.celrep.2016.04.031","article-title":"Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities","volume":"15","author":"Banno","year":"2016","journal-title":"Cell Rep"},{"issue":"1","key":"2022120916074747600_hem2022000395C55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15252\/embr.201439583","article-title":"Stem and progenitor cell dysfunction in human trisomies","volume":"16","author":"Liu","year":"2015","journal-title":"EMBO Rep"},{"issue":"1","key":"2022120916074747600_hem2022000395C56","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41467-021-21064-z","article-title":"The genome-wide impact of trisomy 21 on DNA methylation and its implications for hematopoiesis","volume":"12","author":"Muskens","year":"2021","journal-title":"Nat Commun"},{"issue":"June","key":"2022120916074747600_hem2022000395C57","doi-asserted-by":"crossref","first-page":"636633","DOI":"10.3389\/fonc.2021.636633","article-title":"Molecular mechanisms of the genetic predisposition to acute megakaryoblastic leukemia in infants with Down syndrome","volume":"11","author":"Grimm","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"2022120916074747600_hem2022000395C58","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2012-10-460998","article-title":"Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder","volume":"122","author":"Birger","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2022120916074747600_hem2022000395C59","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gad.1856210","article-title":"miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia","volume":"24","author":"Klusmann","year":"2010","journal-title":"Genes Dev"},{"issue":"5","key":"2022120916074747600_hem2022000395C60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.2021012231","article-title":"The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis","volume":"139","author":"Alejo-Valle","year":"2022","journal-title":"Blood"},{"issue":"6551","key":"2022120916074747600_hem2022000395C61","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf6202","article-title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","volume":"373","author":"Wagenblast","year":"2021","journal-title":"Science"},{"issue":"8","key":"2022120916074747600_hem2022000395C62","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/s41375-020-0854-5","article-title":"Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome","volume":"34","author":"Laurent","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2022120916074747600_hem2022000395C63","doi-asserted-by":"crossref","first-page":"e135937","DOI":"10.1172\/JCI135937","article-title":"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3","volume":"131","author":"Bhansali","year":"2021","journal-title":"J Clin Invest"},{"issue":"6","key":"2022120916074747600_hem2022000395C64","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ng.2949","article-title":"Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation","volume":"46","author":"Lane","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"2022120916074747600_hem2022000395C65","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.celrep.2018.10.061","article-title":"Trisomy of a Down syndrome critical region globally amplifies transcription via HMGN1 overexpression","volume":"25","author":"Mowery","year":"2018","journal-title":"Cell Rep"},{"key":"2022120916074747600_hem2022000395C66","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/erm.2021.6","article-title":"Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view","volume":"23","author":"Hasaart","year":"2021","journal-title":"Expert Rev Mol Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/1\/2021737\/1roberts.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/1\/2021737\/1roberts.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:27Z","timestamp":1670602107000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/1\/493491\/Leukemogenesis-in-infants-and-young-children-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000395","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}